The company seems very focused on 529, the B-Cell market is Huge. I hate to bring up Genta, but they had a an antisense compound that was supposed to work on b-cell (prevent resistance to chemo) and the GNTA CEO claimed that product would work "in everything and with everything", he was talking all cancer types. Ray Warrell was prone to exaggeration.
853 also looks very interesting. If either is a winner shareholders will do very well, if both are winners we could be talking $100-200+ in 3-5+ years if not acquired sooner. They need to accelerate both of these compounds.
S9 what are you doing with your ARNA stock? I sold 1/3 and hedged 1/3 yesterday because I am not bullish in the short term. For me, shorts are making a better short-term case. ARNA communication and progress are weak and slow. Someone needs to tape a cheetah to ARNA and DEA's back (love that commercial).
I have to say, I was not a big fan of Thomas when he was against ARNA, but he was right the first time ARNA was rejected, then later he came around on them, long story short, I am warming up to him as an analyst, he's actually pretty good and I rarely say that. Maybe IMGN will make another run at $15 today.
Just be glad you don't own AFFY today...a reminder the risk of biotech is substantial. I owned it from about $5-6 and sold at $13-15 and watched it go into the $20's. Had been thinking it was becoming a good value again lately, but was afraid of the falling knife chart pattern.